Vertex Pharmaceuticals: The Stock Hasn't Dropped Enough Yet

Group 1 - Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) experienced a price decline of approximately 20% over the past month, which aligns with the anticipated correction [1] - The decline was expected, but the specific reasons for the correction were not detailed in the article [1] Group 2 - The article mentions the author's background as a macroeconomist with over 20 years of experience in investment management, stock broking, and investment banking [1] - The author runs a profile called Long Term Tips (LTT), focusing on opportunities in the green economy, and leads an investing group named Green Growth Giants, which explores deeper opportunities in this sector [1]